【持续性肾脏替代治疗crrt英文精品课件】renal disease overview

Symbol XCPL Rodman Renshaw9thAnnualHealthcareConferenceNovember7 2007 Forward LookingStatements Exceptforstatementsofhistoricalfact themattersdiscussedinthispresentationareforwardlookingandpursuanttothesafeharborprovisionsoftheprivateSecuritiesLitigationReformActof1995 Theseforward lookingstatementsreflectnumerousassumptionsandinvolveavarietyofriskanduncertainties manyofwhicharebeyondthecompany scontrolthatmaycauseactualresultstodiffermateriallyfromstatedexpectations Theseriskfactorsinclude amongothers limitedoperatinghistory difficultyindeveloping exploiting andprotectingproprietarytechnologies theriskthatourtechnologymaynotbeeffective uncertaintyastotheoutcomeoflegalproceedings intensecompetition andsubstantialregulationinthemedicaldeviceandhealthcareindustries asdiscussedintheCompany speriodicreportsfiledwiththeSecuritiesandExchangeCommission availableonitswebsiteathttp www sec gov 2 CompanyOverview MedicaldevicecompanyDevelopingandcommercializingextra corporealmedicaldevicesthatwillreplacethefunctionoffailingorfailedorgansInnovativeplatformtechnologybelievedtobesuperiortothosecurrentlyinuseFocusingonthreerenalreplacementtherapyapplicationsarisingfromplatformtechnology 3 RenalDiseaseOverview AcuteRenalFailureHospital based majorityinIntensiveCareUnit200 000acuterenalfailurepatients 50 mortalityrateEndStageRenalFailureApproximately2million known ESRDpatientsworldwide65 ofpatients expire within5yearsPatient spoorqualityoflifeCareprovidedprimarilyoutsidethehomeNon ambulatoryIntermittentcare SignificantpeaksandvalleysConstantlyillMajoritydisabled 4 Xcorporeal sRenalReplacementTherapyDevices PortableHemodialysisDevice HospitalCRRT AcuteHemodialysisPortableHemodialysisDevice HomeHemodialysis ESRDWearableArtificialKidney HomeHemodialysis ESRD 5 PortableHemodialysisDeviceforHospitalCRRT AcuteHemodialysis 6 AcuteRenalFailure Hospital Prevalence 200 000 yearintheU S with50 mortality majorityhospitalizedinICUsGrowingat10 peryearduetoagingpopulationandincreasingseverityofhospitalizedpatientsContinuousRenalReplacementTherapy CRRT isemergingtherapyofchoice24hour 7daytherapymimicsnormalkidneySlowandgentletherapy Nosuddenvolumeshifts AdoptionofCRRTlimitedbyLaborintensivetherapyExpensivereplacementfluid 7 Xcorporeal sHospitalRenalReplacementDevice Smaller trulyportabledevice 30 40lbs Multifunctional CRRT IntermittentHDSorbent baseddialysateregenerationDecreaseWorkloadforICUstaffNoplumbingrequirementsorbaggeddialysateSimpletouseoperatorinterfaceSnap indisposableunitSimpleset up teardownCosteffectiveDecreaseinmedicalstafftime nurse pharmacist Noneedforbaggeddialysate 180 treatment 8 PortableHemodialysisDeviceforHomeRenalReplacementTherapy 9 ChronicRenalFailure 75MAmericansatriskofdevelopingCRF9thleadingcauseofdeathintheUSNo cure andtherapyfocusesonslowingprogressiontoend stagerenaldiseaseEnd StageRenalDisease 350 000patientsreceivingdialysisHealthcareExpenditures 32b yrin20040 2 populationbut7 ofMedicarebudgetMature cost constrainedindustry 10 HemodialysisforESRD 90 ESRDpts onHDMajorityofpatientsundergotherapy3x wkatanoutpatientclinicfor3 4hours sessionHighmorbidity 12 14dinthehospitalperyearMortalityintheUSremainshighestintheworld 24 inYear1Totalcost 100k yr 11 WhyanOpportunityforXcorporeal RecognitionthatmorehemodialysistreatmentsproducebetterpatientoutcomesReducesmeds e g erythropoietins WWsales 5B ReduceshospitalizationsImprovesqualityoflifeInsurancecompanypotentialnetsavingsof25 Hemodialysisclinicsareexpensivetobuild 1 5Mfora20station 120patientunitMajorefficienciesalreadyachievedwithintheindustry consolidation verticalintegrationCost constraints pricecompressionCapitation singlereimbursementrateBundlingofallservicesincludingmeds onthehorizon 12 HomeHemodialysisisasignificantGrowthOpportunityinESRD PatientBenefitsIncreasedtimeonhemodialysiswithimprovedoutcomesPotentialfordailydialysisImprovedqualityoflife diet sleep timeProviderBenefitsDecreasedneedfornurses techsIncreaseinrevenueswithoutneedforadditionalinfrastructureDecreasedneedforexpensivemedications 13 Comparable NxStageMedical Inc Emerginggrowthhemodialysiscompany SystemOne deviceHomehemodialysis 1 615patients 0 5 marketHospitalCRRTforacuterenalfailureFinancialMetrics 517Mmarketcapitalization 10 25 07 Pro forma 16 7xtrailingtwelvemonthsrevenues13 0 xannualizedQ2 2007revenuesQuarterendedJune30 2007financialhighlights 53Mincash 17Moperatingexpenses 13 5Moperatingloss 14 WhywillXcorporeal sHomeHemodialysisDeviceSucceed MarketforcesdrivinghomehemodialysisPricecompressionMarketingeffortsofNxStageSmaller portabledevice 30 40lbs ImprovedflowratesrelativetoNxStageOpportunityforpatientswithhighBodyMassIndexCosteffectiveNowaterpurificationsystem 100K center Noneedforbaggeddialysate 360 month patient SimpletouseSimpleuserinterfaceSimplesetup teardown 15 ComparisonofHomeHemodialysisDevices 16 WearableArtificialKidney 17 WearableArtificialKidney Disruptive technologyWearable light weightdeviceBatteryoperatedFullyautomated simpletouseDialysateregenerationwithsorbents24hrs 7daystherapywithpotentialtorevolutionizecareofESRDpatients 18 WearableArtificialKidney InitialclinicalstudyconductedwithaprototypedeviceatTheRoyalFreeHospital London8ESRDsubjectsdialyzedformeanof6 4hrsClearancesofcreatinine urea andbeta 2 microglobulinachievedNoadverseeventsreportedSubjectsambulatedbothuntetheredandw oimpactondeviceperformanceCompellingdatapresentedatASNNovember5 2007Publicationsubmittedtopeerreviewjournal 19 RegulatoryStrategy 20 Xcorporeal sProductsAnticipatedApprovalDates 21 ReimbursementCodes CMS Medicare areEstablished 22 RenalReplacementTherapyMarketOpportunity 23 ManagementTeam TerrenPeizerExecutiveChairmanWinsonTang MD FACPChiefOperatingOfficerVictorGura MDChiefMedicalOfficerRobertWeinstein CPA MBAChiefFinancialOfficer CEO Chairman FounderHythiamAmgen Vertex Tularik Isis PacificCapitalGrpCedars SinaiMedCntr AssocClinProf UCLACitiPrivateEquity AbleLabs GECapital 24 ManagementTeam NinaPeled PhD MBASVP Quality RegulatoryJamesBraig MSMESVP ProductDevBarryFulkersonVP HardwareSystemsRussJoseph MSVP DisposableEngineer Hansen Cygnus Amira Lumenis i STAT BMOptiscan SquareOneTech OhioMedicalNxStage COBE Prisma CS3 GambroGishBiomedical Sorin BaxterHealthcare 25 ProductDevelopmentTeam InternalteamofengineerswithexpertiseindialysisequipmentanddisposableswhopreviouslyworkedatCobe Gambro Aksys NxStageandBaxterContractProductDevelopmentGroupinSouthernCaliforniatoleveragetheexpertiseofanadditional10 15engineersManufacturingtobeoutsourced 26 SelectedBoardMembersandScientificAdvisors HansPolaschegg PhDDanGoldberger MSMEKellyMcCrann MBA Fresenius A1008D 2008D 2008H Chairman ExtracorpCir InfusionTechComGlucon OSISystems Optiscan NellcorDaVita PacificCare ProfDentalAssoc KPMG McKinsey 27 SelectedFinancialInformation inmillions BalanceSheet June30 2007 CashandMarketableSecurities 23 0 Totalassets 23 3 Totalliabilities 1 9 Totalstockholders equity 21 5 Workingcapital 21 4Other SharesOutst